Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 4/20 | 0.49 |
| ▸ | GHSR | Q92847 | 16/20 | 0.47 |
| ▸ | ESR1 | P03372 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4481872 | 0.91 | ESR2 (0.49) | ESR2GHSRESR1 | |
| SCHEMBL25895663 | 0.90 | GHSR (0.46) | GHSR | |
| SCHEMBL3056292 | 0.88 | ESR2 (0.52) | ESR2GHSRESR1 | |
| SCHEMBL14863068 | 0.88 | ESR2 (0.52) | ESR2GHSRESR1 | |
| SCHEMBL3075924 | 0.88 | ESR2 (0.52) | ESR2GHSRESR1 | |
| SCHEMBL17391023 | 0.88 | GHSR (0.47) | GHSR | |
| SCHEMBL17726457 | 0.88 | GHSR (0.56) | ESR2GHSRESR1 | |
| SCHEMBL17391030 | 0.87 | GHSR (0.54) | GHSR | |
| SCHEMBL17391179 | 0.87 | GHSR (0.46) | GHSR | |
| SCHEMBL17391103 | 0.87 | GHSR (0.57) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118580188-A | Can be used as ROR gamma regulator aniline compound (B) | 励缔(杭州)医药科技有限公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-113666863-B | Biaryl compounds useful as rory modulators | 励缔(杭州)医药科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-113773251-B | Anilines useful as rory modulators | 励缔(杭州)医药科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| US-20230192620-A1 | ANILINE COMPOUND USED AS RORy REGULATOR | SHANGHAI LITEDD CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192620-A1 | ANILINE COMPOUND USED AS RORy REGULATOR | SHANGHAI LITEDD CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| CN-113773251-A | Anilines useful as ROR gamma modulators | 上海辉启生物医药科技有限公司 | 2021-12-10 | — | — | CN | disclosed |
| CN-113666863-A | Biaryl compounds useful as ROR gamma modulators | 上海辉启生物医药科技有限公司 | 2021-11-19 | — | — | CN | disclosed |
| WO-2021228217-A1 | ANILINE COMPOUND USED AS RORγ REGULATOR | 上海辉启生物医药科技有限公司 | 2021-11-18 | — | — | WO | disclosed |
| WO-2021228216-A1 | BIARYL COMPOUND CAPABLE OF SERVING AS RORγ MODULATOR | 上海辉启生物医药科技有限公司 | 2021-11-18 | — | — | WO | disclosed |
| US-20180319812-A1 | HETEROCYCLIC COMPOUND | ACTION MEDICAL TECHNOLOGIES, LLC | 2018-11-08 | — | — | US | disclosed |
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| EP-1835934-A2 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| WO-2006071940-A2 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | disclosed |
| EP-0658545-B1 | Decahydro-isoquinoline derivatives | LILLY CO ELI (US) | 1999-09-29 | — | — | EP | disclosed |
| EP-0383504-B1 | Decahydro isoquinoline derivatives, process for their preparation and use as medicines | LILLY CO ELI (US) | 1995-07-19 | — | — | EP | disclosed |
| EP-0658545-A1 | Decahydro-isoquinoline derivatives | ELI LILLY AND COMPANY (US) | 1995-06-21 | — | — | EP | disclosed |
| EP-0383504-A2 | Decahydro isoquinoline derivatives, process for their preparation and use as medicines | ELI LILLY AND COMPANY (US) | 1990-08-22 | — | — | EP | disclosed |
| US-4902695-A | ISOQUINOLINE DERIVATIVES; NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1990-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319812-A1 | HETEROCYCLIC COMPOUND | RORC, RORB, RORA | ESR2 248/4885GHSR 675/4885ESR1 656/4885 |
| US-20230192620-A1 | ANILINE COMPOUND USED AS RORy REGULATOR | RORB, RORA, RORC | ESR2 342/4885GHSR 691/4885ESR1 1922/4885 |
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | ESR2 1406/4885GHSR 2085/4885ESR1 978/4885 |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | ESR2 2347/4885GHSR 2365/4885ESR1 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.